During May 1997-November 2000, eight (3%) of 265 kidney transplant recipients at a hospital in California developed an unusual skin condition posttransplant ( Figure 1 ). On clinical examination, the patients had fibrotic skin lesions histologically resembling scleromyxedema on their distal extremities and trunk, resulting in severe contractions and limited mobility. However, the usual IgG lambda paraprotein associated with scleromyxedema was not observed in these patients. Personnel in the dermatopathology section at the University of California, San Francisco, reviewed the biopsies and concluded that this skin disorder had not been described previously. As a result, health-care providers at the hospital where the index patient was treated asked the California Department of Health Services (CDHS) and CDC to assist in the investigation. This report summarizes preliminary findings from the investigation.
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Fibrosing Skin Condition Among Patients with Renal DiseaseUnited States and Europe, 1997-2002
A case was defined as large areas of hardened skin with slightly raised plaques or papules, with or without pigment alteration, in a patient with a skin biopsy indicating increased dermal fibroblasts and mucin and an abnormal dermal collagen bundle pattern. Additional patients were identified by responses to a publication describing the condition (1 ), by colleague referral, and by contacting members of the American Society of Dermatopathology, who were asked to alert other clinicians about the condition and to refer potential patients to CDHS. As of January 2002, 49 patients have been identified throughout the United States and Europe. Although having renal disease is not a part of the case definition, all patients have had underlying renal disease; approximately half have had renal transplantation. No consistently effective treatment exists; however, several patients have improved.
To identify risk factors for this condition, in February 2001, CDHS conducted a case-control study among the eight casepatients at the index hospital, all of whom had renal disease and had undergone renal transplantation. Three controls were selected per case, matched by closest renal transplant date. Medical records for case-and control-patients were reviewed for demographic characteristics, procedures, infections, laboratory values, measures of renal function, and medication exposures. Case-and control-patients were similar Although 94% of RSV detections were reported for the week ending October 30 through the week ending March 25, sporadic detections were reported throughout the year. During July-August 2001, laboratories in Arizona, California, Florida, Hawaii, Nevada, Ohio, Texas, Virginia, Washington, and West Virginia reported sporadic isolates of RSV.
For the current reporting period (July 7 through December 13, 2001), 55 laboratories in 37 states reported results of testing for RSV. Since November 3, 2001, 25 participating laboratories have reported RSV (Figure 1 ). Editorial Note: For the July 2000-June 2001 surveillance period, the number of specimens that tested positive for RSV, median months of onset activity, and regional trends were similar to trends reported during previous years. The duration of the 2000-2001 RSV season also was consistent with that of previous years, including the characteristic earlier onset of RSV outbreaks reported by southern laboratories.
RSV causes bronchiolitis and pneumonia in infants and young children; RSV causes an estimated 31 bronchiolitis associated hospitalizations per 1,000 children aged <1 year per year (6 ) . The rate of RSV-associated hospitalizations is higher in certain populations, such as American Indian/Alaska Native children receiving care through the Indian Health Service (62 per 1,000 children aged <1 per year) (7 ) .
Because RSV infection confers only partial protection from subsequent infection, reinfections occur throughout life (1-3 ). As a result, health-care providers should consider RSV as a cause of acute respiratory disease in all age groups during community outbreaks. Persons with underlying cardiac or pulmonary disease, compromised immune systems, and the elderly are at increased risk for serious complications of RSV infection, including LRTI and death. The disease burden of RSV infections might be >50% of that associated with influenza (8 ) . RSV infection among recipients of bone marrow transplants has been associated with mortality rates >50% (4 ).
Rapid diagnostic techniques for clinicians vary in sensitivity and specificity. Some assays are sensitive for diagnosis in infants and young children but not in older children and adults. PCR-based assays are the most sensitive. No effective treatment for RSV-associated LRTI exists. Ribavirin initially was reported to be an effective treatment; however, subsequent trials could not substantiate a benefit from this therapy (9 ). NREVSS data can alert public health officials and health-care providers to the timing of seasonal RSV activity. Although no RSV vaccine is available, RSV immune globulin intravenous and a humanized murine anti-RSV monoclonal antibody are available as prophylaxis for some high-risk infants and young children (e.g., those born prematurely or with chronic lung disease) to prevent serious RSV disease (5 ) . Contact isolation procedures are recommended for prevention and control of nosocomial transmission of RSV (10 ).
The findings in this report are subject to at least three limitations. First, laboratory data indicate when RSV is circulating in a community; however, the correlation of these data to disease burden in the population is uncertain. Second, few laboratories represent some regions. Finally, diagnostic methods are not standardized among contributing laboratories, and the sensitivity and specificity of these methods probably vary among reporting laboratories.
Additional information and updated data on RSV trends are available at http://www.cdc.gov/ncidod/dvrd/revb/nrevss/ index.htm. Based on data for 17,570 (99%) LD cases, 723 (23%) of 3,143 U.S. counties reported at least one case; approximately 90% of the cases were reported from 124 counties ( Figure 2 ). Reported incidence was >100 cases in 24 counties in Connecticut, Maryland, Massachusetts, New Jersey, New York, Pennsylvania, Rhode Island, and Wisconsin; the highest incidence (943) was reported in Columbia County, New York.
Among 17,551 LD patients with age reported, distribution was bimodal and the median age was 39 years (range: <1-98 years). The highest reported incidence occurred among children aged 5-9 years (9.3) and adults aged 50-59 years (8.2). Among 17,663 patients with sex reported, 9,472 (53.6%) were males, who had a higher incidence compared with females in all age groups. Among 12,977 (73.2%) patients with month of illness onset reported, 7,427 (57.2%) occurred during June (27.3%) and July (29.9%); <5.8% occurred during January, February, and December 2000.
Editorial Note: During 1991-2000, the reported incidence of LD nearly doubled. Most cases continued to occur in northeastern, mid-Atlantic, and north-central states (2, 3) , and the largest proportion of cases continued to be reported among persons aged 5-9 years and 50-59 years, possibly as a result of greater exposure than other groups to infected ticks, less frequent use of personal protective measures, differential use of health-care services, and/or reporting bias. The large number of reported LD cases during June and July reflects the seasonal peak of host-seeking activities of infective nymphalstage vector ticks during May and June in areas where LD is endemic (4) .
The findings in this report are subject to at least three limitations. First, because LD is reported through passive surveillance, LD is underreported, and the distribution and demographics of reported cases could be biased. Second, LD is underreported in areas where disease is endemic and might be overreported in areas where disease is nonendemic. Third, not all LD patients present with typical manifestations; other conditions might be confused with LD and laboratory testing might be inaccurate. *Per 100,000 population. LD can be prevented by reducing tick populations, avoiding tick-infested areas, using repellents, promptly removing attached ticks, and vaccination. Booster doses may be required, but the optimal schedule for this has not been determined. A vaccine was licensed in 1998 that is 76% effective in preventing LD among recipients of 3 doses (5). New strategies for reducing tick vectors of LD include applying acaricides to the principal animal hosts of Ixodes scapularis ticks (i.e., a device for killing ticks on white-tailed deer and a bait box for killing ticks on rodents) (6, CDC, unpublished data, 2001 ). In 2001, community-based LD prevention projects were initiated in Connecticut, Massachusetts, New Jersey, and New York. Through the application of integrated prevention strategies in community-based programs, CDC and state health departments hope to achieve the 2010 national health objective of reducing the incidence of LD to 9.7 in states where LD is endemic (objective 14-8). 
Notice to Readers
Recommended Childhood Immunization Schedule -United States, 2002
Each year, CDC's Advisory Committee on Immunization Practices (ACIP) reviews the recommended childhood immunization schedule to ensure that it is current with changes in manufacturers' vaccine formulations, has revised recommendations for the use of licensed vaccines, and has recommendations for newly licensed vaccines. This report presents the recommended childhood immunization schedule for 2002, which has remained the same in content since January 2001 (1) but has a redesigned format (Figure 1) . given at the recommended age should be given at any subsequent visit when indicated and feasible.
Indicates age groups that warrant special effort to administer those vaccines not given previously. Additional vaccines may be licensed and recommended during the year. Licensed combination vaccines may be used whenever any components of the combination are indicated and the vaccine's other components are not contraindicated. Providers should consult the manufacturers' package inserts for detailed recommendations. † Hepatitis B vaccine (Hep B). All infants should receive the first dose of hepatitis B vaccine soon after birth and before hospital discharge; the first dose also may be given by age 2 months if the infant's mother is HBsAg-negative. Only monovalent hepatitis B vaccine can be used for the birth dose. Monovalent or combination vaccine containing Hep B may be used to complete the series; 4 doses of vaccine may be administered if combination vaccine is used. The second dose should be given at least 4 weeks after the first dose except for Hib-containing vaccine, which cannot be administered before age 6 weeks. The third dose should be given at least 16 weeks after the first dose and at least 8 weeks after the second dose. The last dose in the vaccination series (third or fourth dose) should not be administered before age 6 months. Infants born to HBsAg-positive mothers should receive hepatitis B vaccine and 0.5 mL hepatitis B immune globulin (HBIG) within 12 hours of birth at separate sites. The second dose is recommended at age 1-2 months and the vaccination series should be completed (third or fourth dose) at age 6 months. Infants born to mothers whose HBsAg status is unknown should receive the first dose of the hepatitis B vaccine series within 12 hours of birth. Maternal blood should be drawn at the time of delivery to determine the mother's HBsAg status; if the HBsAg test is positive, the infant should receive HBIG as soon as possible (no later than age 1 week). § Diphtheria and tetanus toxoids and acellular pertussis vaccine (DTaP). The fourth dose of DTaP may be administered as early as age 12 months provided that 6 months have elapsed since the third dose and the child is unlikely to return at age 15-18 months. Tetanus and diphtheria toxoids (Td) is recommended at age 11-12 years if at least 5 years have elapsed since the last dose of tetanus and diphtheria toxoid-containing vaccine. Subsequent routine Td boosters are recommended every 10 years. ¶ Haemophilus influenzae type b (Hib) conjugate vaccine. Three Hib conjugate vaccines are licensed for infant use. If PRP-OMP (PedvaxHIB ® or ComVax ® [Merck] ) is administered at age 2 and 4 months, a dose at age 6 months is not required. DTaP/Hib combination products should not be used for primary immunization in infants at age 2, 4 or 6 months but can be used as boosters following any Hib vaccine.
** Inactivated poliovirus vaccine (IPV).
An all-IPV schedule is recommended for routine childhood poliovirus vaccination in the United States. All children should receive 4 doses of IPV at age 2, 4, and 6-18 months, and 4-6 years. † † Measles, mumps, and rubella vaccine (MMR). The second dose of MMR is recommended routinely at age 4-6 years but may be administered during any visit provided at least 4 weeks have elapsed since the first dose and that both doses are administered beginning at or after age 12 months. Those who have not previously received the second dose should complete the schedule by the visit at age 11-12 years. § § Varicella vaccine. Varicella vaccine is recommended at any visit, at or after age 12 months for susceptible children (i.e., those who lack a reliable history of chickenpox). The format of the 2002 schedule is based on a design developed by the Minnesota Department of Health immunization program; the recommendations and format have been approved by ACIP, the American Academy of Family Physicians, and the American Academy of Pediatrics. The new design highlights the importance of catch-up vaccination, the preadolescent visit, the preference for administering the first dose of the hepatitis B vaccine series at birth, and three vaccines for selected at-risk groups. The importance of assessing whether children aged 24 months-18 years require any catchup vaccination is emphasized by the use of hatched bars. The schedule also underscores the visit at age 11-12 years when immunization status should be reviewed and all necessary vaccines administered.
Hepatitis B Vaccine
The schedule indicates a preference for administering the first dose of hepatitis B vaccine to all newborns soon after birth and before hospital discharge. Administering the first dose of hepatitis B vaccine soon after birth should minimize the risk for infection because of errors in maternal hepatitis B surface antigen (HBsAg) testing or reporting, or from exposure to persons with chronic hepatitis B virus (HBV) infection in the household, and can increase the likelihood of completing the vaccine series. Only monovalent hepatitis B vaccine can be used for the birth dose. Either monovalent or combination vaccine can be used to complete the series. Four doses of hepatitis B vaccine, including the birth dose, may be administered if a combination vaccine is used to complete the series. In addition to receiving hepatitis B immune globulin (HBIG) and the hepatitis B vaccine series, infants born to HBsAg-positive mothers should be tested for HBsAg and antibody to HBsAg (anti-HBs) at age 9-15 months to identify those with chronic HBV infection or those who may require revaccination (2).
Vaccines for Selected Populations
The area below the dashed line (Figure 1 ) displays certain vaccines recommended for use in selected populations. Highrisk children aged 24-59 months should receive catch-up pneumococcal conjugate vaccine (PCV) doses, if indicated (3). Pneumococcal polysaccharide vaccine (PPV) is recommended in addition to PCV for certain high-risk groups (3). The recommendation to administer annual influenza vaccine to high-risk children also appears on the schedule (4).
Vaccine Supply
As a result of the vaccine supply shortage, deferral of some doses of tetanus and diphtheria toxoids (Td), diphtheria and tetanus toxoids and acellular pertussis vaccine (DTaP), and pneumococcal conjugate vaccine (PCV) has been recommended (5-7) ; health-care providers should record patients for whom vaccination has been deferred and should contact them once the supply has been restored.
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